Please assess the completion status of the following clinical trial:

Trial Title: Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. WHO-confirmed AML, other than APL, with no standard treatment options available~2. Age 18 years or older~3. Relapsed or refractory (resistant) disease, as defined by standard criteria~   * Relapsed: Bone marrow blasts ≥5%, reappearance of blasts in the blood, or development of extramedullary disease following achievement of CR/CRi/CRp/MLFS~  * Refractory (resistant): Failure to achieve CR/CRi/MLFS in subjects who survive ≥7 days following completion of initial treatment, with evidence of persistent leukemia by blood and/or bone marrow examination~4. \>14 days since any prior therapy for AML excluding hydroxyurea~5. Willing and able to understand and voluntarily sign a written informed consent~6. Able to adhere to the study visit schedule and other protocol requirements~7. Women of childbearing potential must use an acceptable form of birth control for 28 days prior to beginning study treatment, through the duration of study treatment, and for 3 months after discontinuing study treatment.~Exclusion Criteria:~1. New York Heart Association Class III or IV heart failure~2. Unstable angina pectoris~3. Significant uncontrolled cardiac arrhythmias, including ventricular arrhythmias, congenital long QT syndrome, symptomatic atrial fibrillation, symptomatic bradycardia, right bundle branch block plus left anterior hemiblock or bifasicular block~4. QTc \>500 ms, uncorrectable by managing electrolytes and medications, using the QTcF formula in Appendix D.~5. Active acute graft vs. host disease ≥ grade 2 or active extensive chronic GVHD~6. Relapse after allogeneic stem cell transplantation prior to post-transplant day 30~7. Active central nervous system (CNS) involvement of leukemia (lumbar puncture not required to rule out CNS involvement if not suspected)~8. Uncontrolled psychiatric illness that would limit compliance with requirements~9. Pregnant or breast feeding females~10. Laboratory abnormalities:~    1. Either creatinine \>2.0 mg/dL or creatinine clearance \<30 mL/min~   2. Total bilirubin \> 3 x institutional upper limit of normal (ULN) (unless documented Gilbert's syndrome)~   3. AST or ALT \> 3 x institutional ULN, unless felt to be due to disease involvement~11. Other medical or psychiatric illness or organ dysfunction or laboratory abnormality which, in the opinion of the investigator, would compromise the subject's safety or interfere with data interpretation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Cohort -1 (Type: EXPERIMENTAL): 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
- Cohort 1 (Type: EXPERIMENTAL): 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
- Cohort 2 (Type: EXPERIMENTAL): 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
- Cohort 3 (Type: EXPERIMENTAL): 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV
- Cohort 4 (Type: EXPERIMENTAL): 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV

Based on this trial design, predict the completion outcome and termination type (if applicable).